Kleinostheim, December 15, 2006 – curasan AG (ISIN: DE 000 549 453 8), a company listed in the Prime Standard, has concluded an agreement with the licensor of the REVOIS^® implant system it distributes, whereby the right of pre-emption concerning the purchase of all legal rights associated with the aforementioned product shall be executed with immediate effect. This decision was prompted by the favourable response shown by both national and international experts within the field.

Part of the purchase consideration is to be settled in the form of 500,000 new no-par-value shares, which shall be authorised for trading and are to be issued from Authorised Capital I (Genehmigtes Kapital I). Furthermore, additional purchase price components have been agreed; they are to be financed via the future revenues generated from the distribution of REVOIS^®. Both parties have agreed not to disclose details of the overall purchase price, which is dependent on the product's sales performance.

Thus, curasan AG holds all rights for the manufacture and global marketing of the REVOIS^® implant system, including the rights associated with trademarks and patent filings. In taking this step, the company has ensured that investments in market development will have a sustained positive effective on future corporate performance.